Health News from Medical News Today: Spherix Drug Candidate SPX-106 Shows Statistically Significant Reductions In Serum Triglycerides In Preclinical Testing

Health News from Medical News Today Latest Health News and Medical News posted throughout the day, every day. Spherix Drug Candidate SPX-106 Shows Statistically Significant Reductions In Serum Triglycerides In Preclinical Testing 3 Jun 2011, 8:00 am Spherix Incorporated (NASDAQ: SPEXD) -- an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies -- today announced that its drug candidate, SPX-106, achieved statistically significant reductions in triglycerides and cholesterol when administered in combination with D-tagatose for nine weeks to genetically engineered mice prone to dyslipidemia. SPX-106 is one of five small molecules licensed by Spherix last year... You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed.